Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis
Risch, American Journal of Epidemiology, kwaa093, 27 May 2020, doi:10.1093/aje/kwaa093 (meta analysis)
Risch, Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as.., , American Journal of Epidemiology, kwaa093, 27 May 2020, doi:10.1093/aje/kwaa093 (meta analysis)
May 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Five studies, including two controlled clinical trials, have demonstrated significant outpatient treatment efficacy.
Currently there are 36 HCQ early treatment studies and meta analysis shows:
OutcomeImprovement
Mortality72% lower [57‑81%]
Ventilation67% lower [-710‑99%]
ICU admission28% lower [-17‑55%]
Hospitalization41% lower [28‑52%]
Risch et al., 27 May 2020, peer-reviewed, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be SC RI P Harvey A. Risch Correspondence to Dr. Harvey A. Risch, Department of Chronic Disease Epidemiology, Yale AN U School of Public Health, P.O. Box 208034, New Haven, CT 06520-8034 (e-mail: M harvey.risch@yale.edu; phone: (203) 785-2848) ED Author Affiliations: Department of Chronic Disease Epidemiology, Yale School of Public ED IT Health, New Haven, Connecticut (Harvey A. Risch). Funding: None. N Conflict of Interest: Dr. Risch acknowledges past advisory consulting work with two of the more U than 50 manufacturers of hydroxychloroquine, azithromycin and doxycycline. This past work AL was not related to any of these three medications and was completed more than two years ago. He has no ongoing, planned or projected relationships with any of these companies, nor any G IN other potential conflicts-of-interest to disclose. O RI Running Head: Outpatient Treatment of High-Risk Covid-19 © The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e‐mail: journals.permissions@oup.com. 1 T Ramped-Up Immediately as Key to the Pandemic Crisis Abstract More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that RI P disease have only hospitalization treatment with its high mortality. An outpatient treatment that SC prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. Remdesivir has shown mild AN U effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and M public media, and outpatient trials results are not expected until September. Early outpatient ED illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is ED IT irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than U N 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac AL arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000 Americans now dying each week. These G IN medications need to be widely available and promoted immediately for physicians to prescribe. RI Keywords: Azithromycin; Covid-19; Doxycycline; Hydroxychloroquine; Remdesivir; SARS- O CoV-2; Zinc 2 T number carry antibodies to it. High-risk patients presenting with progressing symptomatic Abbreviations: AZ, azithromycin; CDC, US Centers for Disease Control; FAERS, FDA Adverse Events Reporting System database; FDA, US Food and Drug Administration;..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit